var data={"title":"Tocilizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tocilizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243699?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tocilizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tocilizumab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=tocilizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tocilizumab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773700\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with tocilizumab are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If a serious infection develops, interrupt tocilizumab until the infection is controlled.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before tocilizumab use and during therapy. Treatment for latent infection should be initiated prior to tocilizumab use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated rather than localized disease.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risks and benefits of treatment with tocilizumab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with tocilizumab, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9756027\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actemra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10819878\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Actemra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773705\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Interleukin-6 Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773954\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In patients with giant cell arteritis (GCA) or rheumatoid arthritis (RA), do not initiate if ANC is &lt;2,000/mm<sup>3</sup>, platelets are &lt;100,000/mm<sup>3</sup> or if ALT or AST are &gt;1.5 times ULN. Patients with severe or life-threatening cytokine release syndrome frequently have cytopenias or elevated liver transaminases due to the underlying disease state and/or its treatment; evaluate risk versus benefit of tocilizumab treatment in patients with severe or life-threatening cytokine release syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cytokine release syndrome (due to chimeric antigen receptor-T cell therapy), severe or life-threatening: Note:</b> If clinical improvement does not occur after the first dose, up to 3 additional doses may be administered (with at least an 8 hour interval between consecutive doses). Tocilizumab may be administered as monotherapy or in combination with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Maximum dose: 800 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;30 kg: 12 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;30 kg: 8 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giant cell arteritis:</b> SubQ: 162 mg once every week (in combination with a tapering course of glucocorticoids); based on clinical considerations, may consider 162 mg once every other week (with a tapering course of glucocorticoids). Tocilizumab may be administered as monotherapy following discontinuation of glucocorticoids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> <b>Note:</b> Methotrexate or other <i>nonbiologic</i> disease-modifying antirheumatic drugs (DMARDs) may be continued for the treatment of rheumatoid arthritis. Tocilizumab should not be used in combination with <i>biologic</i> DMARDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 4 mg/kg once every 4 weeks; may be increased to 8 mg/kg once every 4 weeks based on clinical response (maximum dose: 800 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;100 kg: 162 mg once every other week; increase to 162 mg once every week based on clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;100 kg: 162 mg once every week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transitioning from IV therapy to SubQ therapy:</i> Administer the first SubQ dose instead of the next scheduled IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytokine release syndrome (due to bi-specific T-cell engaging therapy), severe or life-threatening (off-label use):</b> IV: 4 mg/kg once; may repeat the dose if clinical improvement does not occur within 24 to 48 hours (Lee 2014). Additional data may be necessary to further define the role of tocilizumab in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12780726\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tocilizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tocilizumab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In patients with polyarticular juvenile idiopathic arthritis (pJIA) or systemic juvenile idiopathic arthritis (SJIA), do not initiate if ANC is &lt;2,000/mm<sup>3</sup>, platelets are &lt;100,000/mm<sup>3</sup> or if ALT or AST are &gt;1.5 times ULN. Patients with severe or life-threatening cytokine release syndrome frequently have cytopenias or elevated liver transaminases due to the underlying disease state and/or its treatment; evaluate risk versus benefit of tocilizumab treatment in patients with severe or life-threatening cytokine release syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cytokine release syndrome (due to chimeric antigen receptor-T cell therapy), severe or life-threatening:</b> Children &ge;2 years of age and Adolescents:<b> Note:</b> If clinical improvement does not occur after the first dose, up to 3 additional doses may be administered (with at least an 8 hour interval between consecutive doses). Tocilizumab may be administered as monotherapy or in combination with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Maximum dose: 800 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;30 kg: 12 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;30 kg: 8 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polyarticular juvenile idiopathic arthritis:</b> Children &ge;2 years of age and Adolescents: IV: <b>Note:</b> Dose adjustment should not be made based solely on a single-visit body weight measurement due to fluctuations in body weight. May be used as monotherapy or in combination with methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;30 kg: 10 mg/kg once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;30 kg: 8 mg/kg once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic juvenile idiopathic arthritis:</b> Children &ge;2 years of age and Adolescents: IV: <b>Note:</b> Dose adjustment should not be made based solely on a single-visit body weight measurement due to fluctuations in body weight. May be used as monotherapy or in combination with methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;30 kg: 12 mg/kg once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;30 kg: 8 mg/kg once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytokine release syndrome (due to bi-specific T-cell engaging therapy), severe or life-threatening (off-label use):</b> IV: 8 mg/kg once; may repeat the dose if clinical improvement does not occur within 24 to 48 hours (Lee 2014). Additional data may be necessary to further define the role of tocilizumab in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773955\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773956\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Not recommended for use in patients with active hepatic disease or hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i> Rheumatoid arthritis (RA) and giant cell arteritis (GCA):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;1 to 3 x ULN: Adjust concomitant disease-modifying antirheumatic drugs (for RA) or immunomodulatory agents (for GCA) as appropriate. For patients receiving IV therapy with persistent increases &gt;1 to 3 x ULN, reduce dose to 4 mg/kg or interrupt until ALT/AST have normalized. For patients receiving SubQ therapy with persistent increases &gt;1 to 3 x ULN, reduce injection frequency to every other week or interrupt until ALT/AST have normalized; increase frequency to every week as clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;3 to 5 x ULN (confirmed with repeat testing): Interrupt until ALT/AST &lt;3 x ULN and follow dosage adjustments recommended for liver enzyme abnormalities &gt;1 to 3 x ULN. For persistent increases &gt;3 x ULN, discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;5 x ULN: Discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773957\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity (anaphylaxis or other clinically significant hypersensitivity reaction): </b> Stop immediately and discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infection (serious infection, opportunistic infection, or sepsis):</b> Interrupt treatment until the infection is controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polyarticular and systemic juvenile idiopathic arthritis:</b> Dose reductions have not been studied; however, dose interruptions are recommended for liver enzyme abnormalities, low neutrophil counts, and low platelets similar to recommendations provided for rheumatoid arthritis. In addition, consider interrupting or discontinuing concomitant methotrexate and/or other medications and hold tocilizumab dosing until the clinical situation has been assessed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis and giant cell arteritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &gt;1,000/mm<sup>3</sup>: Maintain dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 500 to 1,000/mm<sup>3</sup>: Interrupt therapy; when ANC &gt;1,000/mm<sup>3</sup>, resume IV tocilizumab at 4 mg/kg (may increase to 8 mg/kg as clinically appropriate) or resume SubQ tocilizumab at every other week dosing (increase frequency to every week as clinically appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup>: Discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thrombocytopenia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets 50,000 to 100,000/mm<sup>3</sup>: Interrupt therapy; when platelet count is &gt;100,000/mm<sup>3</sup>, resume IV tocilizumab at 4 mg/kg (may increase to 8 mg/kg as clinically appropriate) or resume SubQ tocilizumab at every other week dosing (increase frequency to every week as clinically appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;50,000/mm<sup>3</sup>: Discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773963\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actemra: 80 mg/4 mL (4 mL); 200 mg/10 mL (10 mL); 400 mg/20 mL (20 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actemra: 162 mg/0.9 mL (0.9 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773703\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773701\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf#page=41&amp;token=O2jcAVUvdQ7kpZa0+M5iTOxxpbO0vdzZ9BXAwXJCXPwUuQF9xQLUtk+3Ci6WbaTslySHWawQqYBO/bTN9Fsk836Bay1f/OQKxRcByV7FxMVnlfRDv3IFTW9nufryo2tp&amp;TOPIC_ID=10208\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf#page=41</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773959\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Allow diluted solution for infusion to reach room temperature prior to administration; infuse over 60 minutes using a dedicated IV line. Do not infuse other agents through same IV line. Do not administer IV push or IV bolus. If additional doses are necessary for the management of cytokine release syndrome, the interval between doses should be at least 8 hours. Do not use if opaque particles or discoloration is visible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer the full amount in the prefilled syringe. Allow to reach room temperature prior to use. Do not use if particulate matter or discoloration is visible; solution should be clear and colorless to pale yellow. Rotate injection sites; avoid injecting into moles, scars, or tender, bruised, red, or hard skin. Prefilled syringe is available for use by patients (self-administration). Do not administer subcutaneously for the treatment of polyarticular systemic juvenile arthritis or for systemic juvenile idiopathic arthritis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rheumatoid arthritis: When transitioning from IV administration to SubQ administration, give the first SubQ dose instead of the next scheduled IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Giant cell arteritis: Should only be administered subQ (IV administration is not approved for giant cell arteritis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773707\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytokine release syndrome, severe or life-threatening:</b> Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in patients &ge;2 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giant cell arteritis:</b> Treatment of giant cell arteritis (GCA) in adult patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polyarticular juvenile idiopathic arthritis:</b> Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients &ge;2 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic juvenile idiopathic arthritis:</b> Treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients &ge;2 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50023773\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cytokine release syndrome (severe or life-threatening; due to BiTE therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50169190\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tocilizumab may be confused with sarilumab.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773765\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence as reported for monotherapy, except where noted. Combination therapy refers to use in rheumatoid arthritis with nonbiological disease-modifying antirheumatic drugs or use in systemic juvenile idiopathic arthritis or polyarticular juvenile idiopathic arthritis in trials where most patients (~70% to 80%) were taking methotrexate at baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum cholesterol (&gt;240 mg/dL; 19% to 20%; &gt;1.5 to 2 x ULN; combination therapy; children and adolescents &lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&le;36%; grades 3/4: &lt;1%), increased serum AST (&le;22%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion-related reaction (combination therapy; 4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (1% to 6%), peripheral edema (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 7%), dizziness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2%), dermatological reaction (combination therapy; 1% [includes pruritus, urticaria])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased LDL cholesterol (9% to 10%; &gt;1.5 to 2 x ULN; combination therapy; children and adolescents &lt;1% to 2%), hypothyroidism (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (children and adolescents &le;5%), abdominal pain (2%), oral mucosa ulcer (2%), gastric ulcer (&lt;2%), stomatitis (&lt;2%), weight gain (&lt;2%), gastritis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (combination therapy; grade 3: 2% to 7%; grade 4: &lt;1%), thrombocytopenia (combination therapy; 1% to 2%), leukopenia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (SubQ: Including erythema, pruritus, pain, and hematoma; 4% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Nephrolithiasis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (7%), nasopharyngitis (7%), bronchitis (3%), cough (&lt;2%), dyspnea (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Infection: Infection, serious infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anaphylactoid reaction, angioedema, aspergillosis, candidiasis, cellulitis, chronic inflammatory demyelinating polyneuropathy, cryptococcosis, diverticulitis, gastroenteritis, gastrointestinal perforation, herpes zoster, hypersensitivity reaction, hypersensitivity pneumonitis, hypertriglyceridemia, hypotension, increased HDL cholesterol, malignant neoplasm (including breast and colon cancer), multiple sclerosis, nausea, otitis media, pneumonia, pneumocystosis, reactivation of latent Epstein-Barr virus, septic arthritis, sepsis, Stevens-Johnson syndrome, tuberculosis, urinary tract infection, varicella</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to tocilizumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773713\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated liver enzymes: Tocilizumab is associated with transaminase elevations. Monitor transaminases. Treatment should be discontinued in patients who develop elevated ALT or AST &gt;5 x ULN. Patients receiving concomitant hepatotoxic drugs (eg, methotrexate) are at an increased risk of developing elevated transaminases; elevations are typically reversible and do not result in clinically evident hepatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI perforation: Use with caution in patients at increased risk for GI perforation; perforation has been reported, typically secondary to diverticulitis. Monitor for new-onset abdominal symptoms; promptly evaluate if new symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Neutropenia and thrombocytopenia may occur; may require treatment interruption, dose or interval modification, or discontinuation. Monitor neutrophils and platelets. Do not initiate treatment in patients with giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, or systemic juvenile idiopathic arthritis with an ANC &lt;2,000/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>; discontinue treatment for ANC &lt;500/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpes zoster reactivation: Herpes zoster reactivation has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Therapy is associated with increases in total cholesterol, triglycerides, LDL, and/or HDL; monitor ~4 to 8 weeks after initiation, then approximately every 6 months. Hyperlipidemia should be managed according to current guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: May cause hypersensitivity or anaphylaxis; anaphylactic events including fatalities have been reported with IV administration; hypersensitivity reactions have occurred in patients who were premedicated, in patients with and without a prior history of hypersensitivity, and as early as the first infusion. Medications for the treatment of hypersensitivity reactions should be available for immediate use. Patients should seek medical attention if symptoms of hypersensitivity reaction occur with SubQ use. Stop immediately and permanently discontinue treatment in patients who develop a hypersensitivity reaction to tocilizumab. In clinical studies, reactions requiring treatment discontinuation included generalized erythema, rash, and urticaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Serious and potentially fatal infections (including active tuberculosis, invasive fungal, bacterial, viral, protozoal, and other opportunistic infections) have been reported in patients receiving tocilizumab; infection may lead to hospitalization or death. Most of the serious infections have occurred in patients on concomitant immunosuppressive therapy. Patients should be closely monitored for signs and symptoms of infection during and after treatment. If serious infection occurs during treatment, withhold tocilizumab until infection is controlled. Prior to treatment initiation, carefully consider risk versus benefit in patients with chronic or recurrent infections,</b> tuberculosis exposure, history of or current opportunistic infection, underlying conditions predisposing to infection, or patients residing in or with travel to areas of endemic tuberculosis or endemic mycosis. The most common serious infections occurring have included pneumonia, UTI, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, and bacterial arthritis. Do not administer tocilizumab to a patient with an active infection, including localized infection. Interrupt treatment for serious infection, opportunistic infection, or sepsis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Use of tocilizumab may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined; however, malignancies were observed in clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Tuberculosis (pulmonary or extrapulmonary) has been reported in patients receiving tocilizumab; both reactivation of latent infection and new infections have been reported. Patients should be tested for latent tuberculosis infection before and during therapy; consider treatment of latent tuberculosis used prior to tocilizumab treatment. Some patients who test negative prior to therapy may develop active infection; monitor for signs and symptoms of tuberculosis during and after treatment in all patients.</b> Patients should be evaluated for tuberculosis risk factors with a tuberculin skin test prior to starting therapy. Consider antituberculosis treatment in patients with a history of latent or active tuberculosis if adequate treatment course cannot be confirmed, and for patients with risk factors for tuberculosis despite a negative test.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Use with caution in patients with preexisting or recent onset CNS demyelinating disorders; rare cases of CNS demyelinating disorders (multiple sclerosis and chronic inflammatory demyelinating polyneuropathy) have occurred. All patients should be monitored for signs and symptoms of demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is not recommended in patients with active hepatic disease or hepatic impairment. Monitor ALT and AST. Do not initiate treatment if ALT or AST is &gt;1.5 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biological disease-modifying antirheumatic drugs (DMARDs): Concomitant use with other biological DMARDs (eg, TNF blockers, IL-1 receptor blockers, anti-CD20 monoclonal antibodies, selective costimulation modulators) has not been studied and should be avoided due to the increased risk of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Infection has been reported at a higher incidence in elderly patients compared with younger adults; use with caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: SubQ administration is only indicated for adult patients with rheumatoid arthritis and giant cell arteritis (GCA). Do not use SubQ injection for IV infusion. Do not administer IV for the treatment of GCA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of infection from live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300151\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9774917\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10208&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Tocilizumab may enhance the adverse/toxic effect of Abatacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: Tocilizumab may enhance the immunosuppressive effect of Anti-TNF Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): Tocilizumab may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Tocilizumab may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773709\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. As pregnancy progresses, monoclonal antibodies are increasingly transported across the placenta, with the largest amount transferred during the third trimester. Immune response in infants exposed to tocilizumab in utero may be affected. Consider risks/benefits prior to administering live or live-attenuated vaccines to infants exposed to tocilizumab during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established to monitor outcomes of women exposed to tocilizumab during pregnancy. Health care providers or pregnant patients are encouraged to register (877-311-8972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773711\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tocilizumab is present in human milk. However, maternal immunoglobulins are excreted in human milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773961\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Latent TB screening prior to therapy initiation (all patients); neutrophils, platelets, ALT/AST (prior to therapy, 4 to 8 weeks after start of therapy, and every 3 months thereafter [rheumatoid arthritis]); neutrophils, platelets, ALT/AST (prior to therapy, at second infusion, and every 2 to 4 weeks [systemic juvenile idiopathic arthritis] or 4 to 8 weeks [polyarticular juvenile idiopathic arthritis] thereafter); additional liver function tests (eg, bilirubin) as clinically indicated; lipid panel (prior to, at 4 to 8 weeks following initiation, and approximately every 6 months during therapy); monitor all patients for signs and symptoms of infection (prior to, during, and after therapy); signs and symptoms of CNS demyelinating disorders</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773888\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tocilizumab is an antagonist of the interleukin-6 (IL-6) receptor. Endogenous IL-6 is induced by inflammatory stimuli and mediates a variety of immunological responses. Inhibition of IL-6 receptors by tocilizumab leads to a reduction in cytokine and acute phase reactant production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773890\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset (cytokine release syndrome [CRS]): Median time to defervescence: 4 hours (Fitzgerald 2017); Fever and hypotension often resolve within a few hours (Lee 2014); Blood pressure stabilization: 1 to 3 days (Abboud 2017; Maude 2014b). A median of 1 dose (range: 1 to 4) was required for management of CRS due to chimeric antigen receptor T-cell therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Children: 2.54 L (systemic juvenile idiopathic arthritis [SJIA]), 4.08 L (polyarticular juvenile idiopathic arthritis [pJIA]); Adults: 6.4 L (rheumatoid arthritis [RA]), 7.46 L (giant cell arteritis [GCA])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Terminal, single dose: 6.3 days (concentration-dependent; may be increased up to 16 to 23 days [children] or 11 to 13 days [adults] at steady state)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Concentration dependent: Adults: RA: Up to 5 days (every-other-week dosing) or up to 13 days (every-week dosing); GCA: 4.2 to 7.9 days (every other week dosing) or 18.3 to 18.9 days (every-week dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ: ~3 days (for every-week dosing); ~4.5 days (for every-2-week dosing)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322788\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Actemra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/4 mL (4 mL): $500.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/10 mL (10 mL): $1,250.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/20 mL (20 mL): $2,500.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Actemra Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">162 mg/0.9 mL (0.9 mL): $1,181.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962019\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actemra (AE, AR, AU, BB, BR, CL, CN, CO, CU, EC, HK, ID, IL, IN, JO, JP, KR, LB, LK, MY, NZ, PE, PH, QA, SA, SG, TH, TW, VN);</li>\n      <li>Actemra SC (MY, TH);</li>\n      <li>Aktemra (UA);</li>\n      <li>RoActemra (AT, BE, CH, CR, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HN, HR, IE, IS, LT, LU, LV, MT, NI, NL, NO, PA, PL, PT, RO, RU, SE, SI, SK, SV, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27318038\"></a>Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. <i>Biol Blood Marrow Transplant.</i> 2016;22(10):1851-1860.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/27318038/pubmed\" target=\"_blank\" id=\"27318038\">27318038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actemra (tocilizumab) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emery P, Keystone E, Tony HP, et al, &ldquo;IL-6 Receptor Inhibition With Tocilizumab Improves Treatment Outcomes in Patients With Rheumatoid Arthritis Refractory to Anti-Tumour Necrosis Factor Biologicals: Results from a 24-Week Multicentre Randomised Placebo-Controlled Trial,&rdquo; <i>Ann Rheum Dis</i>, 2008, 67(11):1516-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/18625622/pubmed\" target=\"_blank\" id=\"18625622\">18625622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27632680\"></a>Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. <i>Crit Care Med.</i> 2017;45(2):e124-e131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/27632680/pubmed\" target=\"_blank\" id=\"27632680\">27632680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genovese MC, McKay JD, Nasonov EL, et al, &ldquo;Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs: The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study,&rdquo; <i>Arthritis Rheum</i>, 2008, 58(10):2968-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/18821691/pubmed\" target=\"_blank\" id=\"18821691\">18821691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imagawa T, Yokota S, Mori M, et al, &ldquo;Safety and Efficacy of Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody, in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis,&rdquo; <i>Mod Rheumatol</i>, 2012, 22(1):109-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/21667343/pubmed\" target=\"_blank\" id=\"21667343\">21667343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24876563\"></a>Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124(2):188-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/24876563/pubmed\" target=\"_blank\" id=\"24876563\">24876563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maini RN, Taylor PC, Szechinski J, et al, &ldquo;Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who had an Incomplete Response to Methotrexate,&rdquo; <i>Arthritis Rheum</i>, 2006, 54(9):2817-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/16947782/pubmed\" target=\"_blank\" id=\"16947782\">16947782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24667956\"></a>Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. <i>Cancer J</i>. 2014a;20(2):119-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/24667956/pubmed\" target=\"_blank\" id=\"24667956\">24667956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25317870\"></a>Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. <i>N Engl J Med</i>. 2014b;371(16):1507-1517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/25317870/pubmed\" target=\"_blank\" id=\"25317870\">25317870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimoto N, Hashimoto J, Miyasaka N, et al, &ldquo;Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, and IL-6 Inhibitor (SAMURAI): Evidence of Clinical and Radiographic Benefit from an X-Ray Reader-Blinded Randomised Controlled Trial of Tocilizumab,&rdquo; <i>Ann Rheum Dis</i>, 2007, 66(9):1162-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/17485422/pubmed\" target=\"_blank\" id=\"17485422\">17485422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimoto N, Miyasaka N, Yamamoto K, et al, &ldquo;Long-Term Safety and Efficacy of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in Monotherapy, in Patients With Rheumatoid Arthritis (the STREAM study): Evidence of Safety and Efficacy in a 5-Year Extension Study,&rdquo; <i>Ann Rheum Dis</i>, 2009, 68(10):1580-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/19019888/pubmed\" target=\"_blank\" id=\"19019888\">19019888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimoto N, Miyasaka N, Yamamoto K, et al, &ldquo;Study of Active Controlled Tocilizumab Monotherapy for Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (SATORI): Significant Reduction in Disease Activity and Serum Vascular Endothelial Growth Factor by IL-6 Receptor Inhibition Therapy,&rdquo; <i>Mod Rheum</i>, 2009, 19(1):12-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/18979150 /pubmed\" target=\"_blank\" id=\"18979150 \">18979150 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oldfield V, Dhillon S, and Plosker GL, &ldquo;Tocilizumab: A Review of its Use in the Management of Rheumatoid Arthritis,&rdquo; <i>Drugs</i>, 2009, 69(5):609-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/19368420/pubmed\" target=\"_blank\" id=\"19368420\">19368420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plushner SL, &ldquo;Tocilizumab: An Interleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis,&rdquo; <i>Ann Pharmacother</i>, 2008, 429(11):1660-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/18957621/pubmed\" target=\"_blank\" id=\"18957621\">18957621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smolen JS, Beaulieu A, Rubbert-Roth A, et al, &ldquo;Effect of Interleukin-6 Receptor Inhibition With Tocilizumab in Patients With Rheumatoid Arthritis (OPTION study): A Double-Blind, Placebo-Controlled, Randomised Trial,&rdquo; <i>Lancet</i>, 2008, 371(9617):987-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tocilizumab-drug-information/abstract-text/18358926/pubmed\" target=\"_blank\" id=\"18358926\">18358926</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10208 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9773700\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9756027\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10819878\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9773705\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9773954\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12780726\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9773955\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9773956\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9773957\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9773963\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9773703\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9773701\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9773959\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9773707\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50023773\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50169190\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9773765\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9773712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9773713\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300151\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9774917\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9773709\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9773711\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9773961\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9773888\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9773890\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322788\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962019\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10208|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tocilizumab-patient-drug-information\" class=\"drug drug_patient\">Tocilizumab: Patient drug information</a></li><li><a href=\"topic.htm?path=tocilizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">Tocilizumab: Pediatric drug information</a></li></ul></div></div>","javascript":null}